HIV Treatment: Comparing DOR/3TC and DTG/3TC

We are studying whether a new two-drug regimen can maintain viral suppression in people living with HIV who are currently stable on a three-drug treatment. This trial will also assess various health outcomes and side effects over time.

>2 years6-10 visitsConfirmation phase (III)No PlaceboStandard MedicinesOralInfectious Diseases

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dolutegravir
Dolutegravir is a substance that helps control HIV infection by blocking the virus from inserting its genetic material into human cells.
Doravirine
Doravirine is a substance that helps control HIV infection by preventing the virus from multiplying.
Lamivudine
Lamivudine is a substance that helps treat HIV and hepatitis B by stopping the viruses from multiplying.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
CHU De Martinique
Infectious and Tropical Diseases
Amilly, France
Centre Hospitalier Universitaire D'Angers
Infectious and Tropical Diseases
Angers, France
Centre Hospitalier Victor Dupouy
Immuno-Hématologie, Unité VIH-IST
Argenteuil, France
Sponsor: Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.